Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy

Jeannette Y. Lee, Ishwori Dhakal, Corey Casper, Ariela Noy, Joel M. Palefsky, Missak Haigentz, Susan E. Krown, Richard F. Ambinder, Ronald T. Mitsuyasu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLink® Health Plan Claims Database. The expected number of cancer cases in the general population for each gender-age group (<30, 30-39, 40-49, 50-59, and >60 years) was estimated using incidence rates from the Surveillance Epidemiology and End Results (SEER) program. Standardized incidence ratios (SIRs) were estimated using their 95% confidence intervals (CIs). Compared to the general population, incidence rates for HIV-infected adults were elevated (SIR, 95% CI) for Kaposi sarcoma (46.08; 38.74-48.94), non-Hodgkin lymphoma (4.22; 3.63-4.45), Hodgkin lymphoma (9.83; 7.45-10.84), and anal cancer (30.54; 25.62-32.46) and lower for colorectal cancer (0.69; 0.52-0.76), lung cancer (0.70; 0.54, 0.77), and prostate cancer (0.54; 0.45-0.58). Commercially insured, treated HIV-infected adults had elevated rates for infection-related cancers, but not for common non-AIDS defining cancers.

Original languageEnglish (US)
Article number2138259
JournalJournal of Cancer Epidemiology
Volume2016
DOIs
StatePublished - Jan 1 2016

Fingerprint

HIV
Incidence
Neoplasms
SEER Program
Confidence Intervals
Anus Neoplasms
Population
Therapeutics
Kaposi's Sarcoma
Health Insurance
Insurance
Hodgkin Disease
Non-Hodgkin's Lymphoma
Prescriptions
Colorectal Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Age Groups
Databases
Health

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Genetics
  • Public Health, Environmental and Occupational Health

Cite this

Lee, J. Y., Dhakal, I., Casper, C., Noy, A., Palefsky, J. M., Haigentz, M., ... Mitsuyasu, R. T. (2016). Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy. Journal of Cancer Epidemiology, 2016, [2138259]. https://doi.org/10.1155/2016/2138259
Lee, Jeannette Y. ; Dhakal, Ishwori ; Casper, Corey ; Noy, Ariela ; Palefsky, Joel M. ; Haigentz, Missak ; Krown, Susan E. ; Ambinder, Richard F. ; Mitsuyasu, Ronald T. / Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy. In: Journal of Cancer Epidemiology. 2016 ; Vol. 2016.
@article{971aca1fab2a47e88b6aeccf7dcbbfe0,
title = "Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy",
abstract = "The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLink{\circledR} Health Plan Claims Database. The expected number of cancer cases in the general population for each gender-age group (<30, 30-39, 40-49, 50-59, and >60 years) was estimated using incidence rates from the Surveillance Epidemiology and End Results (SEER) program. Standardized incidence ratios (SIRs) were estimated using their 95{\%} confidence intervals (CIs). Compared to the general population, incidence rates for HIV-infected adults were elevated (SIR, 95{\%} CI) for Kaposi sarcoma (46.08; 38.74-48.94), non-Hodgkin lymphoma (4.22; 3.63-4.45), Hodgkin lymphoma (9.83; 7.45-10.84), and anal cancer (30.54; 25.62-32.46) and lower for colorectal cancer (0.69; 0.52-0.76), lung cancer (0.70; 0.54, 0.77), and prostate cancer (0.54; 0.45-0.58). Commercially insured, treated HIV-infected adults had elevated rates for infection-related cancers, but not for common non-AIDS defining cancers.",
author = "Lee, {Jeannette Y.} and Ishwori Dhakal and Corey Casper and Ariela Noy and Palefsky, {Joel M.} and Missak Haigentz and Krown, {Susan E.} and Ambinder, {Richard F.} and Mitsuyasu, {Ronald T.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1155/2016/2138259",
language = "English (US)",
volume = "2016",
journal = "Journal of Cancer Epidemiology",
issn = "1687-8558",
publisher = "Hindawi Publishing Corporation",

}

Lee, JY, Dhakal, I, Casper, C, Noy, A, Palefsky, JM, Haigentz, M, Krown, SE, Ambinder, RF & Mitsuyasu, RT 2016, 'Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy', Journal of Cancer Epidemiology, vol. 2016, 2138259. https://doi.org/10.1155/2016/2138259

Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy. / Lee, Jeannette Y.; Dhakal, Ishwori; Casper, Corey; Noy, Ariela; Palefsky, Joel M.; Haigentz, Missak; Krown, Susan E.; Ambinder, Richard F.; Mitsuyasu, Ronald T.

In: Journal of Cancer Epidemiology, Vol. 2016, 2138259, 01.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy

AU - Lee, Jeannette Y.

AU - Dhakal, Ishwori

AU - Casper, Corey

AU - Noy, Ariela

AU - Palefsky, Joel M.

AU - Haigentz, Missak

AU - Krown, Susan E.

AU - Ambinder, Richard F.

AU - Mitsuyasu, Ronald T.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLink® Health Plan Claims Database. The expected number of cancer cases in the general population for each gender-age group (<30, 30-39, 40-49, 50-59, and >60 years) was estimated using incidence rates from the Surveillance Epidemiology and End Results (SEER) program. Standardized incidence ratios (SIRs) were estimated using their 95% confidence intervals (CIs). Compared to the general population, incidence rates for HIV-infected adults were elevated (SIR, 95% CI) for Kaposi sarcoma (46.08; 38.74-48.94), non-Hodgkin lymphoma (4.22; 3.63-4.45), Hodgkin lymphoma (9.83; 7.45-10.84), and anal cancer (30.54; 25.62-32.46) and lower for colorectal cancer (0.69; 0.52-0.76), lung cancer (0.70; 0.54, 0.77), and prostate cancer (0.54; 0.45-0.58). Commercially insured, treated HIV-infected adults had elevated rates for infection-related cancers, but not for common non-AIDS defining cancers.

AB - The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLink® Health Plan Claims Database. The expected number of cancer cases in the general population for each gender-age group (<30, 30-39, 40-49, 50-59, and >60 years) was estimated using incidence rates from the Surveillance Epidemiology and End Results (SEER) program. Standardized incidence ratios (SIRs) were estimated using their 95% confidence intervals (CIs). Compared to the general population, incidence rates for HIV-infected adults were elevated (SIR, 95% CI) for Kaposi sarcoma (46.08; 38.74-48.94), non-Hodgkin lymphoma (4.22; 3.63-4.45), Hodgkin lymphoma (9.83; 7.45-10.84), and anal cancer (30.54; 25.62-32.46) and lower for colorectal cancer (0.69; 0.52-0.76), lung cancer (0.70; 0.54, 0.77), and prostate cancer (0.54; 0.45-0.58). Commercially insured, treated HIV-infected adults had elevated rates for infection-related cancers, but not for common non-AIDS defining cancers.

UR - http://www.scopus.com/inward/record.url?scp=84999018264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999018264&partnerID=8YFLogxK

U2 - 10.1155/2016/2138259

DO - 10.1155/2016/2138259

M3 - Article

AN - SCOPUS:84999018264

VL - 2016

JO - Journal of Cancer Epidemiology

JF - Journal of Cancer Epidemiology

SN - 1687-8558

M1 - 2138259

ER -